Document:

THIS WARRANT AND THE SECURITIES UNDERLYING
THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”) AND MAY NOT
BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION
THEREFROM UNDER SUCH SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS AND THE RULES AND REGULATIONS THEREUNDER. 

 

AVRA SURGICAL ROBOTICS, INC.

 

WARRANT

 

TO PURCHASE COMMON STOCK OF THE COMPANY

 

	Warrant No. ___	Issue Date: ______, 2012

 

FOR VALUE RECEIVED,
AVRA SURGICAL ROBOTICS, INC., a Delaware corporation (the “Company”), grants the following rights to the purchaser
executing a signature page attached hereto, and its permitted assigns, heirs, executors and administrators (individually and collectively,
the “Holder”), as of the date first written above (“Issue Date”). This warrant (the “Warrant”)
to has been issued by the Company pursuant to the terms and conditions of a warrant purchase agreement, dated ______, 2012 (the
“Purchase Agreement”) by and between the Company and the Holder.

 

Section 1.          Grant.

 

The Holder is hereby
granted the right (collectively, the “Purchase Rights”), in accordance with the terms and conditions of this Warrant,
from the date hereof until the expiration of the “Exercise Period” (as defined below), to purchase from the Company
that number of fully paid and non-assessable shares of the Common Stock of the Company, set forth in Section 2 hereof, at the “Exercise
Price” (as defined below), upon delivery of this Warrant to the Company with the Notice of Exercise form attached as Exhibit
1 hereto, duly executed, and upon tender of the Exercise Price for the shares of Common Stock to be purchased.

 

Section 2.          Number
of Shares of Common Stock Purchasable.

 

2.1      Subject to the other provisions
of this Section 2, this Warrant entitles the Holder to purchase from time to time up to _______________ shares (the "Warrant
Shares") of the Company’s common stock, par value $.0001 per share (the “Common Stock”).

 

2.2      In case prior to the expiration
of the Purchase Rights by exercise or by the terms of this Warrant, the Company shall undertake any reclassification, forward stock
split, reverse stock split, stock dividend or any similar proportionately-applied change (collectively, a “Reclassification”)
of outstanding shares of Common Stock (other than a change solely in, of, or from par value), the Holder shall thereafter be entitled,
upon exercise of this Warrant for the same total consideration as presently required, to purchase the kind and amount of shares
of stock and other securities and property receivable upon such Reclassification by a holder of the number of shares of Common
Stock which this Warrant entitles the Holder hereof to purchase immediately prior to such Reclassification. Notice of any such
Reclassification shall be given to the Holder pursuant to Section 12 hereof.

 

    	-1-

    	 

    
 

2.3      In case prior to the expiration
of the Purchase Rights by exercise or by the terms of this Warrant, the Company shall determine to consolidate or merge with, or
convey all, or substantially all, of its property or assets to, any other corporation or corporations, or dissolve, liquidate or
wind up, then, as a condition precedent to such consolidation, merger, conveyance, dissolution, liquidation or winding up, notice
shall be given to the Holder pursuant to Section 12 hereof and lawful and adequate provision shall be made whereby the Holder shall
thereafter have the right to receive from the Company or the successor corporation, as the case may be, upon the basis and upon
the terms and conditions specified in this Warrant, in lieu of the shares of Common Stock of the Company theretofore purchasable
upon the exercise of the Purchase Rights, such shares of stock, securities, or assets as may be issued or payable with respect
to, or in exchange for, the number of shares of Common Stock of the Company theretofore purchasable upon the exercise of the Purchase
Rights had such consolidation, merger, conveyance, dissolution, liquidation or winding up not taken place; and in any such event
the rights of the Holder to an adjustment of the number of shares of Common Stock purchasable upon the exercise of the Purchase
Rights as herein provided, shall continue and be preserved in respect of any stock or securities which the Holder becomes entitled
to purchase.

 

Section 3.          Exercise
Period; Registration Statement Notice. The Purchase Rights represented hereby shall be exercisable in whole or in part
from time to time after the date of issuance of this Warrant until 5:00 p.m. Eastern time on the third anniversary of the Issue
Date hereof (the “Exercise Period”).

 

Section 4.          Exercise. The
Purchase Rights represented by this Warrant are exercisable upon the terms and conditions set forth herein at the option of the
Holder in whole at any time and in part, but not for less than 100 shares at a time, at any time and from time to time during the
Exercise Period upon the delivery of the Notice of Exercise form attached hereto as Exhibit 1 to the Company with such notice
duly executed and upon payment in cash, wire transfer or bank cashier’s check of the Exercise Price. The Purchase Rights
shall be deemed to have been exercised, and the Holder shall be deemed to have become a stockholder of record of the Company for
the purposes of receiving dividends and for all other purposes whatsoever with respect to the shares of Common Stock so purchased,
as of the date of delivery of such properly executed Notice of Exercise accompanied by proper tender of the Exercise Price at the
office of the Company. As promptly as practicable on or after such date, and in any event within five (5) business days thereafter,
the Company at its expense shall issue and deliver, or cause to be issued and delivered, to the person or persons entitled to receive
the same, a certificate or certificates for the number of shares issuable upon such exercise. In the event that this Warrant is
exercised in part, the Company at its expense shall execute and deliver a new Warrant of like tenor exercisable for the number
of shares for which this Warrant may then be exercised.          

 

    	-2-

    	 

    
 

Section 5.          Exercise
Price. The exercise price for each share of Common Stock
issuable to the Holder hereunder shall be $5.00 per share, subject to adjustment as provided in Section 2 and otherwise herein
(the “Exercise Price”).

 

Section 6.          Company’s
Warranties and Covenants as to Capital Stock. The Company has taken all action necessary and appropriate to properly
authorize, reserve and issue those shares of Common Stock issuable to the Holder pursuant to this Warrant including an authorization
of issuance and setting of exercise price. The Common Stock deliverable on the exercise of the Purchase Rights represented hereby
shall, when issued, be duly and validly issued, fully paid and nonassessable. The Company shall at all times reserve and hold available
sufficient shares of Common Stock to satisfy the Purchase Rights..

 

Section 7.          Transfer;
Compliance With Securities Laws; Right of Company to Request Opinion of Counsel Confirming Such Compliance; Holder Responsible
for Costs of Transfer Including Reasonable Counsel Fees. The
Purchase Rights shall be registered on the books of the Company, which shall be kept by it at its principal office for that purpose.
This Warrant and the Common Stock issuable upon exercise of the Purchase Rights, may not be transferred or assigned in whole or
in part without compliance with all applicable federal and state securities laws by the transferor and the transferee, including,
if requested by the Company, an opinion of counsel satisfactory to the Company to the effect that the transfer or assignment is
in compliance with applicable securities laws. Subject to such compliance, the Purchase Rights shall be transferable on said books,
in whole or in part, by the Holder in person or by duly authorized attorney upon surrender of this Warrant properly endorsed by
the Holder executing the Permitted Transfer or Assignment Form attached hereto and made a part hereof as Exhibit 2. All
reasonable and documented costs associated with any transfer or assignment, including, without limitation, the reasonable fees
of counsel to the Company shall be borne by the transferor or assignor. The Company agrees that, while the Purchase Rights remain
valid and outstanding, its stock transfer books shall not be closed for any purpose whatsoever except under arrangements which
shall insure to persons exercising warrants or applying for transfer of stock all rights and privileges which they might have had
or received if the stock transfer books had not been closed and they had exercised their Purchase Rights at any time during which
such transfer book shall have been closed.

 

Section 8.          Charges,
Taxes and Expenses. Issuance of certificates for shares
of Common Stock issuable upon the exercise of this Warrant or any portion thereof (and issuance of a replacement Warrant certificate
in the event of partial exercise) shall be made without charge to the Holder hereof for any issue taxes or any other incidental
expenses in respect of the issuance of such certificates to and in the name of the registered Holder of this Warrant, all of which
taxes and expenses shall be paid by the Company, and such certificates shall be issued in the name of the Holder of this Warrant.
Certificates will be issued in a name other than that of the Holder upon the request of a Holder and payment by the Holder of any
applicable transfer taxes and compliance with all applicable securities laws and with all applicable provisions of this Warrant
including but not limited to Section 7 hereof.

 

Section 9.          Exchange
for Other Denominations. This Warrant is exchangeable
for new certificates of like tenor and date representing in the aggregate the right to purchase the number of shares purchasable
hereunder in denominations designated by the Holder at the time of surrender. In the event of the purchase, at any time prior to
the expiration of the Exercise Period, of less than all of the shares of Common Stock purchasable hereunder, the Company shall
cancel this Warrant upon surrender thereof, and shall promptly execute and deliver to the Holder hereof a new warrant of like tenor
and date for the balance of the shares purchasable hereunder.

 

    	-3-

    	 

    
 

Section 10.          Loss,
Theft, Destruction or Mutilation of Warrant. Upon receipt
by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant,
and, in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon reimbursement to the
Company of all reasonable and documented expenses incidental thereto, and upon surrender of this Warrant, if mutilated, the Company
shall promptly make and deliver a new warrant of like tenor and date, in lieu of this Warrant and cancel this Warrant.

 

Section 11.          Registration
Rights.

 

11.1          For purposes
of this Section 11 the capitalized terms in this Section 11 shall have the following meanings:

 

(a)          “Family
Member” means a) with respect to any individual, such individual’s spouse, any descendants (whether natural or
adopted), any trust all of the beneficial interests of which are owned by any of such individuals or by any of such individuals
together with any organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended, the estate of any
such individual, and any corporation, association, partnership or limited liability company all of the equity interests of which
are owned by those above described individuals, trusts or organizations and (b) with respect to any trust, the owners of the beneficial
interests of such trust.

 

(b)          “Holder”
means the purchaser hereof and any of its respective successors and Permitted Assignees who acquire rights in accordance with this
Warrant with respect to any Registrable Securities (defined below) directly or indirectly from the Holder or from any Permitted
Assignee (defined below).

 

(c)          “Permitted
Assignee” means (a) with respect to a partnership, its partners or former partners in accordance with their partnership
interests, (b) with respect to a corporation, its stockholders in accordance with their interest in the corporation, (c) with respect
to a limited liability company, its members or former members in accordance with their interest in the limited liability company,
(d) with respect to an individual party, any Family Member of such party, or (e) an entity that is controlled by, controls, or
is under common control with a transferor.

 

(d)          “Registrable
Securities” means the shares of Common Stock underlying this Warrant but excludes (i) any Registrable Securities sold
by a person in a transaction pursuant to a registration statement filed under the Securities Act, (ii) any Registrable Securities
that are at the time subject to an effective registration statement under the Securities Act or (iii) any Registrable Securities
that may be sold without volume limitations or other restrictions under Securities Act Rule 144 or successor rule thereof.

 

    	-4-

    	 

    
 

11.2          Piggyback
Registration.  

 

(a)          In
the event the Company shall determine in its sole discretion to register with the SEC for sale any Common Stock, for its own account
or for the account of others, other than (i) a registration relating solely to employee benefit plans or securities issued or issuable
to employees, consultants (to the extent the securities owned or to be owned by such consultants could be registered on Form S-8)
or any of their Family Members (including a registration on Form S-8) or (ii) a registration relating solely to a Securities Act
Rule 145 transaction or a registration on Form S-4 in connection with a merger, acquisition, divestiture, reorganization or similar
event, the Company shall promptly give to the Holder (and in no event shall such notice be given less than ten (10) calendar days
prior to the filing of such registration statement), and shall, include all of the Registrable Securities specified in a written
request delivered by the Holder thereof within five (5) calendar days after receipt of such written notice from the Company. However,
the Company may, without the consent of the Holder, withdraw such registration statement prior to its becoming effective if the
Company or such other stockholders have elected to abandon the proposal to register the securities proposed to be registered thereby.

 

(b)          Notwithstanding
the foregoing, if such registration undertaken by the Company is in connection with an underwritten public offering, and the underwriter
in such public offering reasonably determines that inclusion of all of the Registrable Securities in such registration would be
detrimental to the successful completion of the offering contemplated in such registration statement, and based on such determination
recommends inclusion in such registration statement of fewer or none of the Registrable Securities of the Holder, then (i) the
number of Registrable Securities of the Holder included in such registration statement shall be reduced pro-rata among the holders
of all Registrable Securities (based upon the number of Registrable Securities requested to be included in the registration), if
the Company after consultation with the underwriter(s) recommends the inclusion of fewer Registrable Securities, or (ii) none of
the Registrable Securities of the Holder shall be included in such registration statement, if the Company after consultation with
the underwriter(s) recommends the inclusion of none of such Registrable Securities; provided, however, that if securities are being
offered for the account of other persons or entities as well as the Company, such reduction shall not represent a greater fraction
of the number of Registrable Securities intended to be offered by the Holder than the fraction of similar reductions imposed on
such other persons or entities (other than the Company).

 

(c)          Notwithstanding
the other registration obligations set forth herein, in the event the SEC informs the Company that all of the Registrable Securities
cannot, as a result of the application of Rule 415, be registered for resale on a single registration statement, the Company agrees
to promptly (i) inform the Holder thereof, (ii) use its commercially reasonable efforts to file amendments to the registration
statement as required by the SEC and/or (iii) withdraw the registration statement and file a new registration statement (a “New
Registration Statement”), in either case covering the maximum number of Registrable Securities permitted to be registered
by the SEC, on Form S-1 or such other form available to register for resale the Registrable Securities as a secondary offering;
provided, however, that prior to filing such amendment or New Registration Statement, the Company shall be obligated to
use its commercially reasonable efforts to advocate with the SEC  for the registration of all of the Registrable Securities
in accordance with the SEC guidance, including without limitation, advocating that the offering contemplated by the Registration
Statement is a valid secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415. 
In the event the Company amends the registration statement or files a New Registration Statement, as the case may be, under clauses
(ii) or (iii) above, the Company will use its commercially reasonable efforts to file with the SEC, as promptly as allowed by the
SEC or by SEC guidance provided to the Company or to registrants of securities in general, one or more registration statements
on Form S-1 or such other form available to register for resale those Registrable Securities that were not registered for resale
on the registration statement, as amended, or the New Registration Statement.  The foregoing notwithstanding, if the Company
is required to limit the number of shares that it can include on such resale registration statement or New Registration Statement
by regulation or the requirements of the SEC or any exchange, then, notwithstanding any other registration rights of the Holder,
the number of Registrable Securities to be included on such registration statement and New Registration Statement shall be allocated
to those certain holders of securities as shall be determined by the Company, in its sole discretion.

 

    	-5-

    	 

    
 

11.3          Expenses.
The Company shall bear all expenses incurred by the Company in compliance with the registration obligation of the Company, including,
without limitation, all registration and filing fees, printing expenses, fees and disbursements of counsel for the Company incurred
in connection with any registration, qualification or compliance pursuant to this Warrant and all underwriting discounts, selling
commissions and expense allowances applicable to the sale of any securities by the Company for its own account in any registration.
All underwriting discounts, selling commissions and expense allowances applicable to the sale by the Holder of Registrable Securities
and all fees and disbursements of counsel for the Holder shall be borne by the Holder.

 

11.4          Indemnification.

 

(a)          To
the extent permitted by law, the Company will indemnify the Holder, each of its officers, directors, agents, employees and partners,
and each person controlling the Holder, with respect to each registration of Registrable Securities under the Securities Act and
qualification of Registrable Securities under state securities laws effected pursuant to this Warrant, against all claims, losses,
damages and liabilities (or actions, proceedings or settlements in respect thereof) arising out of or based on (i) any untrue statement
(or alleged untrue statement) of a material fact contained in any prospectus, offering circular or other document prepared and
filed by the Company pursuant to which Registrable Securities were registered under the Act (including any related registration
statement, notification or the like) incident to any such registration or qualification, or (ii) any omission (or alleged omission)
to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any
violation by the Company of the Act or any rule or regulation thereunder applicable to the Company and relating to action or inaction
required of the Company in connection with any such registration or qualification, and subject to the provisions of this section
below, will reimburse the Holder, each of its officers, directors, agents, employees and partners, and each person controlling
the Holder, for any legal and any other expenses as they are reasonably incurred in connection with investigating and defending
any such claim, loss, damage, liability or action, provided, however, that the Company will not be liable to the extent
that any such claim, loss, damage, liability or expense arises out of or is based on any failure of the Holder or his representatives
to distribute Registrable Securities in accordance with applicable laws (including failure to deliver any required preliminary
prospectus or final prospectus (or the final prospectus as amended and supplemented) at or before the written confirmation of the
sale of such Registrable Securities); nor shall the Company be liable in any such case for any such loss, claim, damage, liability
or action to the extent that it arises out of or is based upon a violation which occurs in reliance upon and in conformity with
written information furnished expressly for use in connection with such registration by the Holder, any such partner, officer,
director, employee, agent or controlling person of the Holder, or any such underwriter or any person who controls any such underwriter.
Notwithstanding the foregoing, the indemnity contained in this subsection shall not apply to amounts paid in settlement of any
such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent
shall not be unreasonably withheld).

 

    	-6-

    	 

    
 

(b)          To
the extent permitted by law, the Holder will indemnify the Company, and its directors, officers, agents, employees and each underwriter,
if any, of the Company’s securities covered by such a registration statement, each person who controls the Company or such
underwriter within the meaning of the Act and the rules and regulations thereunder, and their respective counsel against all claims,
losses, damages and liabilities (or actions in respect thereof) arising out of or based on any failure of Holder or its representatives
to distribute Registrable Securities in accordance with applicable laws (including failure to deliver any required preliminary
prospectus or final prospectus (or the final prospectus as amended and supplemented to the extent such amendment or supplement
is timely provided to the Holder) as required by applicable law); or any untrue statement (or alleged untrue statement) of a material
fact contained in any such registration statement, prospectus, offering circular or other document, or any omission (or alleged
omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading,
and will reimburse the Company and its directors, officers, partners, persons, underwriters or control persons for any legal or
any other expenses as they are reasonably incurred in connection with investigating or defending any such claim, loss, damage,
liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement)
or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance
upon and in conformity with written information furnished to the Company by such Holder for specific use in such registration statement,
prospectus, offering circular or other document; provided, however, that the indemnity agreement contained in this subsection shall
not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without
the consent of the Holder, which consent shall not be unreasonably withheld or delayed.

 

(c)          Each
party entitled to indemnification under this section (the “Indemnified Party”) shall give notice to the party
required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual
knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any
such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense
of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not unreasonably
be withheld), and the Indemnified Party may participate in such defense at such party’s expense; and provided further that
if counsel to the Indemnified Party shall reasonably believe that a material conflict of interest is likely to exist if the same
counsel were to represent such Indemnified Party and the Indemnifying Party then the Indemnified Party may retain one separate
counsel at the expense of the Indemnifying Party; and provided further that the failure of any Indemnified Party to give notice
as provided herein shall not relieve the Indemnifying Party of its obligations under this Warrant unless and only to the extent
that such failure to give notice results in material prejudice to the Indemnifying Party. No Indemnifying Party, in the defense
of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any judgment or
enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such
Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified Party shall furnish
such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall
be reasonably required in connection with defense of such claim and litigation resulting therefrom.

 

    	-7-

    	 

    
 

If the indemnification
provided for in this section is held by a court of competent jurisdiction to be unavailable to an Indemnified Party with respect
to any loss, liability, claim, damage or expense referred to herein, then the Indemnifying Party, in lieu of indemnifying such
Indemnified Party hereunder, shall contribute to the amount paid or payable by such Indemnified Party as a result of such loss,
liability, claim, damage or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party
on the one hand and of the Indemnified Party on the other in connection with the statements or omissions which resulted in such
loss, liability, claim, damage or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying
Party and of the Indemnified Party shall be determined by reference to, among other things, whether the untrue or alleged untrue
statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party
or by the Indemnified Party and the parties’ relative intent, knowledge, access to information and opportunity to correct
or prevent such statement or omission.

 

Section 12.          Notices
Including Certificate of Company In Event of Adjustment.

 

(a)          Whenever
the number of shares purchasable hereunder or Exercise Price shall be adjusted pursuant to Section 2 hereof, the Company shall
issue a certificate signed by its Chief Financial Officer or its President or such other appropriate officer, setting forth, in
reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated,
and the number of shares purchasable hereunder or new Exercise Price after giving effect to such adjustment, and shall cause a
copy of such certificate to be mailed (by first-class mail, postage prepaid) to the Holder of this Warrant.

 

(b)          In
case:

 

(i)          the
Company shall take a record of the holders of its Common Stock for the purpose of entitling them to receive any dividend or other
distribution, or any right to subscribe for or purchase any shares of stock of any class or any other securities, or to receive
any other right, or

 

(ii)          of
any capital reorganization of the Company, any reclassification of the capital stock of the Company, any consolidation or merger
of the Company with or into another corporation, or any conveyance of all or substantially all of the assets of the Company to
another corporation, or

 

    	-8-

    	 

    
 

(iii)          of
any voluntary dissolution, liquidation or winding-up of the Company,

 

then, and in each such case, the Company
shall mail or deliver or cause to be mailed or delivered to the Holder or Holders a notice specifying, as the case may be, (A)
the date on which a record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character
of such dividend, distribution or right, or (B) the date on which such reorganization, reclassification, consolidation, merger,
conveyance, dissolution, liquidation or winding-up is to take place, and the time, if any is to be fixed, as of which the holders
of record of Common Stock shall be entitled to exchange their shares of Common Stock for securities or other property deliverable
upon such reorganization, reclassification, consolidation, merger, conveyance, dissolution, liquidation or winding-up. Such notice
shall be mailed or delivered at least 15 business days prior to the date therein specified.

 

(c)          All
notices, requests, consents and demands required by this Warrant shall be in writing and shall be personally delivered or mailed,
postage prepaid, to the Company at:

 

AVRA SURGICAL ROBOTICS,
INC.

c/o Stamell & Schager,
LLP

1 Liberty Plaza, 35th
Floor

New York, NY 10006

Attn: Jared Stamell

 

with a copy (which shall not constitute
notice) to:

 

Richardson & Patel
LLP

750 Third Avenue, 9th
Floor

New York, New York
10017

Attn: David Feldman,
Esq.

Fax: (917) 677-8165

 

and to the Holder at the address(es)
set forth on the Holder's signature page or at such other address(es) as the Company or Holder may designate by ten (10) days advance
written notice to the other party.

 

All notices required or permitted hereunder
shall be in writing and shall be deemed effectively given: (i) upon personal delivery to the party to be notified, (ii) when sent
by confirmed facsimile if sent during normal business hours of the recipient, if not, then on the next business day, (iii) five
(5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv) one (1) day
after deposit with a nationally recognized overnight courier, specifying next day delivery with written verification of receipt.

 

Section
13.          Miscellaneous. This Warrant shall not entitle
the Holder to any of the rights of a stockholder of the Company. This Warrant shall be binding upon the Company’s
successors. This Warrant shall be governed, construed and enforced in accordance with the laws of the State of Delaware. In
case any provision of this Warrant shall be invalid, illegal or unenforceable, or partially invalid, illegal or
unenforceable, the provision shall be enforced to the extent, if any, that it may legally be enforced and the validity,
legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. This Warrant
shall any term hereof may be changed, waived, discharged or terminated only by a statement in writing signed by the party
against which enforcement of such change, waiver, discharge or termination is sought. The headings in this Warrant are for
purposes of reference only, and shall not limit or otherwise affect any of the terms hereof.

 

[Signatures appear on following page.]

 

    	-9-

    	 

    
 

IN WITNESS WHEREOF,
the Company has caused this Warrant to be duly executed and delivered on its behalf as of the Issue Date set forth above.

 

	 	COMPANY:	 
	 	 	 	 
	 	AVRA SURGICAL ROBOTICS, INC.	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	By:	 	 
	 	 	Barry F. Cohen	 
	 	 	President	 

 

 

 

HOLDER:

 

______________________________________

Name

 

______________________________________

Signature

 

______________________________________

Capacity in which signed (if other than
individual)

 

 

Holder Address:

 

______________________________________

 

______________________________________

 

______________________________________

 

______________________________________

 

    	 

    	 

    
 

EXHIBIT 1

 

 

NOTICE OF EXERCISE PURSUANT TO

ATTACHED WARRANT

 

 

______________, 20___

 

 

To: AVRA SURGICAL ROBOTICS, INC.

 

(1)          The
undersigned, the Holder of record of the attached Warrant of AVRA SURGICAL ROBOTICS, INC., hereby exercises the option granted
by the Purchase Rights evidenced by the attached Warrant [and hereby tenders payment of the Exercise Price as determined by the
Warrant] to purchase upon the terms set forth in such Warrant [________] shares of Common Stock, which constitutes all [or a portion]
of the shares of Common Stock issued pursuant to the Purchase Rights represented by this Warrant of AVRA SURGICAL ROBOTICS, INC.
All capitalized terms used but not defined in this notice have the meanings assigned to such terms in the Warrant.

 

(2)          In
exercising this Warrant, the undersigned hereby confirms and acknowledges that (a) the undersigned has complied with all terms
and conditions of the Purchase Agreement as defined in the Warrant, including the requirement that the Holder is an “accredited”
investor, (b) the shares of the Common Stock to be issued are being acquired solely for investment and solely for the account of
the undersigned, (c) the undersigned will not offer, sell or otherwise dispose of any such shares of Common Stock except under
circumstances that will not result in a violation of the Securities Act of 1933, as amended, or any applicable state securities
laws, and (d) as required under the terms of the Purchase Agreement, the certificate or certificates representing said shares of
Common Stock shall bear a restrictive legend prohibiting and restricting transfer of such shares except in compliance with applicable
federal and state securities laws.

 

(3)          Please
issue a certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name
as is specified below.

 

(4)          Please
issue a new Warrant for the unexercised portion of the attached Warrant, if any, in the name of the undersigned or in such other
name as is specified below:

 

	ATTEST:	 	HOLDER:	 
	 	 	 	 
	 	 	 	 
	 	 	By:	 
	 	 	 	 
	 	 	Name:	 
	 	 	 	 
	 	 	Title:	 

 

(If certificates for Common Stock or new
Warrants are requested in a name other than the undersigned, be advised that the delivery of the certificates and/or new Warrants
will be delayed until the Company assures itself that such change is permitted under Section 7 of the Warrant that such change
does not violate applicable federal and state securities laws.)

 

    	 

    	 

    
 

EXHIBIT 2

 

PERMITTED TRANSFER OR ASSIGNMENT FORM

 

NOTE: THIS ASSIGNMENT BEARS A RESTRICTIVE
LEGEND BELOW

 

FOR VALUE RECEIVED,
the undersigned Holder of record of this Warrant of AVRA SURGICAL ROBOTICS, INC. (the “Company”), which is dated ___________,
hereby sells, assigns and transfers unto the Assignee named below all of the rights, including, without limitation, the Purchase
Rights (as such term is defined in this Warrant) of the undersigned under the within Warrant, with respect to the number of shares
of Common Stock set forth below:

 

	Name of Transferee/Assignee	Address	No. of Shares

 

 

and does hereby irrevocably constitute
and appoint the Secretary of AVRA SURGICAL ROBOTICS, INC. to make such transfer on the books of AVRA SURGICAL ROBOTICS, INC., maintained
for the purpose, with full power of substitution in the premises.

 

Attached hereto, if
and to the extent requested by the Company, is an opinion of counsel that the assignment does not violate or is exempt from, any
federal and state securities laws. As provided in the Warrant, including but not limited to Section 7 of the Warrant, the Company
may, in its sole discretion, decide whether such opinion is satisfactory, and Assignee and Holder agree to any reasonable delay
in transfer caused by such evaluation and further acknowledge and agree that they shall bear all reasonable and documented costs
associated with any transfer or assignment, including, without limitation, the reasonable fees of counsel to the Company shall
be borne by the transferor or assignor.

 

The undersigned also
represents that, by assignment hereof, the Assignee acknowledges that this Warrant and the shares of Common Stock to be issued
upon exercise hereof or conversion thereof are being acquired for investment and that the Assignee will not offer, sell or otherwise
dispose of this Warrant or any shares of stock to be issued upon exercise hereof or conversion thereof except under circumstances
which will not result in a violation of the Securities Act of 1933, as amended, or any state securities laws. Further, the Assignee
has acknowledged that upon exercise of this Warrant, the Assignee shall, if requested by the Company, confirm in writing, in a
form satisfactory to the Company, that the shares of Common Stock so purchased are being acquired for investment and not with a
view toward distribution or resale in violation of applicable securities laws.

 

Accordingly, the
following restrictive legend is made applicable to this assignment (and to this Warrant and securities covered by this Warrant
as assigned hereby to Assignee):

 

 

[INSERT RESTRICTIVE LEGEND]

 

    	 

    	 

    
 

This Assignment and this Warrant and
the securities underlying this Warrant as assigned hereby, have not been registered under the Securities Act of 1933, as amended
(the “Securities Act”), and may not be offered, sold or otherwise transferred, assigned, pledged or hypothecated in
the absence of such registration or an exemption therefrom under such Securities Act, any applicable state securities laws and
the rules and regulations thereunder.

 

	Dated: 	 	 	HOLDER:	 	 
	 	 	 	 	 	 	 
	 	 	 	 	By:	 	 
	 	 	 	 	Name:	 	 
	 	 	 	 	Title:	 	 
	 	 	 	 	 	 	 
	Dated:	 	 	ASSIGNEE: 	 	 
	 	 	 	 	 	 	 
	 	 	 	 	By:	 	 
	 	 	 	 	Name:	 	 
	 	 	 	 	Title:SECURITIES PURCHASE
AGREEMENT

 

THIS SECURITIES
PURCHASE AGREEMENT (this “Agreement”), dated as of the date set forth on the signature page hereto, by and
among AVRA Surgical Robotics, Inc., a Delaware corporation (the “Company”) with an address at c/o Stamell &
Schager, LLP, 1 Liberty Plaza 35th Floor, New York, NY 10006, and the purchasers executing a signature page attached hereto (individually,
an "Purchaser" and collectively, the "Purchasers").

 

W I T
N E S S E T H:

 

WHEREAS, each of the
Purchasers has invested in and is a stockholder of AVRA Surgical, Inc. (the "Original AVRA") with the intent of
investing in a surgical robotics company (the "Original AVRA Investment"); and

 

WHEREAS, certain affiliates
of the Original AVRA acquired the Company with the intent of establishing a surgical robotics business;

 

WHEREAS, in connection
with satisfying the purpose and intent of the Original AVRA Investment, the Company desires to issue and sell to the Purchasers
and the Purchasers desire, severally and not jointly, to purchase from the Company up to an aggregate of 26,839,754 shares (the
“Shares”) of the common stock, par value $.0001 per share, of the Company (the “Common Stock”)
at a per share purchase price equal to $0.0001 per share (the "Purchase Price")

 

NOW, THEREFORE, in
consideration of the premises, conditions and promises herein contained, the parties hereto agree as follows:

 

		1.	PURCHASE AND SALE OF SHARES

 

1.1          Sale
and Issuance of Shares

 

(a)         Sale
of Shares. Upon the terms and subject to the conditions set forth in this Agreement, in consideration of the Purchase Price
and for the purpose of satisfying the intent of the Original AVRA Investment, the Company agrees to issue and sell to each of the
Purchasers and each Purchaser agrees to purchase from the Company, the number of Shares set forth on the signature page hereto
for the aggregate Purchase Price set forth on each Purchaser's signature page.

 

(b)         Place
of Closing. The completion of the purchase and sale of the Shares hereunder (the “Closing”) shall take place by
electronic communication at such time as the Company and the Purchasers agree, subject to the satisfaction of all conditions herein.

 

(c)         Deliveries.

 

(i)         The
Company shall deliver to each Purchaser a certificate representing the number of Shares purchased by such Purchaser, duly executed
by the Company, within 10 business days after Closing; and

 

(ii)         At
or prior to the Closing, the Purchasers shall deliver to the Company the Purchase Price in immediately available funds to such
account as the Company may designate.

 

(iii)         The
Company and the Purchasers shall deliver this Agreement duly executed at the Closing.

 

    	 

    	 

    
 

1.2          Use
of Proceeds. The Company shall use the proceeds of the sale of the Shares for general working
capital purposes.

 

		2.	REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE COMPANY.

 

The Company hereby
represents, warrants and covenants to the Purchasers as follows:

 

2.1          Organization;
Good Standing. The Company has been duly incorporated or organized, is validly existing as a
corporation or other applicable business entity and is in good standing under the laws of the State of Delaware and has the requisite
power to carry on its business as now conducted.

 

2.2          Authorization.
The Company has the requisite power and authority to enter into this Agreement and to carry out its obligations hereunder. The
execution, delivery and performance of this Agreement by the Company and the consummation by the Company of the transactions contemplated
hereby have been duly authorized by the board of directors of the Company and no other actions on the part of the Company are necessary
to authorize this Agreement or the transactions contemplated hereby. This Agreement has been duly and validly executed and delivered
by the Company and constitutes a valid and binding agreement of the Company, enforceable against the Company in accordance with
its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency or other similar laws affecting the enforcement
of creditors' rights generally or by general principles of equity. The Company shall have authorized the issuance of the Shares,
pursuant to the terms and conditions of this Agreement, and, when issued, sold and delivered in accordance with this Agreement
for the consideration described herein, shall be duly authorized and validly issued, are fully paid and nonassessable, and were
issued in accordance with the registration or qualification provisions of any applicable securities laws or pursuant to valid exemptions
therefrom.

 

2.3          Consents.
The Company is not required to obtain any consent, waiver, authorization or order of, give any
notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or
other person in connection with the valid execution, delivery and performance by the Company or the offer, sale or issuance of
the Shares other than the filing of a Form D Notice of Exempt Offering of Securities (“Form D”) with the Commission,
if deemed advisable by the Company, and such filings as are required to be made under applicable state securities laws. 

 

2.4          Compliance.
To the knowledge of the Company’s officers and directors, no claim has been filed against the Company alleging a violation
of any applicable laws or regulations of foreign, federal, state and local governments and all agencies thereof. The Company holds
all of the material permits, licenses, certificates or other authorizations of foreign, federal, state or local governmental agencies
required for the conduct of its business as presently conducted.

 

2.5          Questionable
Payments. Neither the Company, nor any employee, agent or representative of the Company, has,
directly or indirectly, made any bribes, kickbacks, illegal payments or illegal political contributions using the Company’s
funds or made any payments from the Company’s funds to any governmental officials for improper purposes or made any illegal
payments from the Company to obtain or retain business.

 

    	-2-

    	 

    
 

		3.	REPRESENTATIONS AND WARRANTIES OF THE PURCHASERS.

 

Each Purchaser hereby
represents and warrants to the Company, solely as to itself, as follows:

 

3.1          Authorization.
Each Purchaser has full power and authority to enter into this Agreement, to perform its obligations
hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. This Agreement constitutes a valid
and legally binding obligation of such Purchaser, enforceable in accordance with their respective terms except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’
rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other
equitable remedies.

 

3.2          Investment.
Each Purchaser is acquiring the Shares solely for investment and for the Purchaser’s own
account, not as a nominee or agent, and not with a view to the resale or distribution thereof. The Purchaser
has no agreement or arrangement, formal or informal, with any person to sell or transfer all or any part of any of the Shares and
the Purchaser has no plans to enter into any such agreement or arrangement.

 

3.3          Accredited
Purchaser. The Purchaser is an “Accredited Investor” as that term is defined in Rule
501 of Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”) and
has truthfully and accurately completed the Accredited Investor Questionnaire attached to this Agreement as Exhibit A and
will submit to the Company such further assurances of such status as may be reasonably requested by the Company.
The Purchaser represents to the Company that any information which the undersigned has heretofore
furnished or is furnishing herewith to the Company is complete and accurate and may be relied upon by the Company in determining
the availability of an exemption from registration under Federal and state securities laws in connection with the offering and
sale of the Shares.

 

3.4          Adequate
Information. The Purchaser and the Purchaser’s attorney, accountant, purchaser
representative and/or tax advisor, if any (collectively, the “Advisors”), have had a reasonable opportunity to ask
questions of and receive answers from the Company’s officers and any other persons authorized by the Company to answer such
questions, concerning, among other related matters, this Agreement, the Shares, and the business, financial condition, results
of operations and prospects of the Company and all such questions have been answered by the Company to the full satisfaction of
the Purchaser and its Advisors, if any. The Purchaser also acknowledges that the Company may
repurchase or issue and sell shares of the Common Stock of the Company at a per share purchase price that may be greater than the
Purchase Price paid for the Shares and such Purchaser has had the opportunity to consult with its Advisors with respect to the
tax implications regarding the purchase of the Shares.

 

3.5          Non-Reliance.
In evaluating the suitability of an investment in the Company, the Purchaser has
not relied upon any representation or other information (oral or written) other than as stated in this Agreement or as contained
in documents so furnished to the Purchaser or its Advisors, if any, by the Company in writing. The Purchaser is not relying on
the Company, or any of its respective employees or agents with respect to the legal, tax, economic and related considerations of
an investment in any the Shares and the Purchaser has relied on the advice of, or has consulted with, only its own Advisors.

 

    	-3-

    	 

    
 

3.6          No
General Solicitation. Each Purchaser is unaware of, is in no way relying on, and did not become
aware of the offering of the Shares through or as a result of, any form of general solicitation or general advertising including,
without limitation, any article, notice, advertisement or other communication published in any newspaper, magazine or similar media
or broadcast over television, radio or over the Internet, in connection with the offering and sale of the Shares and is not purchasing
the Shares as a result of any seminar or meeting to which the Purchaser was invited by, or any solicitation of a subscription by,
a person not previously known to the Purchaser in connection with investments in securities generally.

 

3.7          Investor
Suitability. The Purchaser understands and agrees that purchase of the Shares is a high risk
investment and the Purchaser is able to afford an investment in a speculative venture having the risks and objectives of the Company
and has adequate means of providing for Purchaser’s current financial needs and foreseeable contingencies and has no need
for liquidity from its investment in the Shares for an indefinite period of time. The Purchaser must bear the substantial economic
risks of the investment in the Shares indefinitely because none of the Shares may be sold, hypothecated or otherwise disposed of
unless subsequently registered under the Securities Act and applicable state securities laws or an exemption from such registration
is available. The investment is a suitable one for the Purchaser. 

 

3.8          Specific
Purpose. Each Purchaser that is an entity represents that it was not formed for the specific
purpose of acquiring the Shares, is duly organized, validly existing and in good standing under the laws of the state of its organization,
the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of any law or its
charter or other organizational documents, such entity has full power and authority to execute and deliver this Agreement and to
carry out the provisions hereof and thereof and to purchase and hold the Shares, the execution and delivery of this Agreement has
been duly authorized by all necessary action, this Agreement has been duly executed and delivered on behalf of such entity and
is a legal, valid and binding obligation of such entity; or (iii) if executing this Agreement in a representative or fiduciary
capacity, represents that it has full power and authority to execute and deliver this Agreement in such capacity and on behalf
of the Purchaser and the Purchaser has full right and power to perform pursuant to this Agreement and make an investment in the
Company, and represents that this Agreement constitutes a legal, valid and binding obligation of the Purchaser. The execution and
delivery of this Agreement will not violate or be in conflict with any order, judgment, injunction, agreement or controlling document
to which the Purchaser is a party or by which it is bound.

 

3.9          Brokers
or Finders. Each Purchaser has taken no action which would give rise to any claim by any person
for brokerage commissions, finders’ fees or the like relating to this Agreement or the transactions contemplated hereby.

 

3.10          Restricted
Securities. None of the Shares are registered under the Securities Act of 1933,
as amended (the “Securities Act”), or any state securities laws. The Purchaser acknowledges that the
Shares have not been recommended by any US Federal or State securities commission or regulatory authority and have not confirmed
the accuracy or determined the adequacy of this Agreement. The Purchaser understands
that the offering and sale of the Shares is intended to be exempt from registration under the Securities Act, by virtue of Section
4(2) thereof and, if deemed advisable by the Company, the provisions of Regulation D promulgated thereunder, based, in part, upon
the representations, warranties and agreements of the Purchaser contained in this Agreement. The Purchaser understands that
the Shares may not be sold, transferred or otherwise disposed of without registration under the Securities Act or an exemption
therefrom.

 

    	-4-

    	 

    
 

3.11          Legend.
The certificates representing the Shares shall be endorsed with the legend in substantially the
form set forth below:

 

THE SECURITIES REPRESENTED
HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY
NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT THERETO
UNDER SUCH ACT AND APPLICABLE LAWS OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF SUCH ACT AND APPLICABLE LAWS AND AN OPINION
OF COUNSEL TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED.

 

		4.	MISCELLANEOUS.

 

4.1          Expenses.
The Company and the Purchasers will each pay their own expenses incurred in connection with the
negotiation, preparation, execution and delivery of this Agreement. 

 

4.2          Survival.
 Except as otherwise provided in this Agreement, all representations, warranties, covenants and
agreements contained in this Agreement shall survive the execution and delivery of this Agreement and the Closing. No investigation
by any of the Purchasers shall affect the survival or enforceability of the Company’s representations, warranties, covenants
and agreements contained in this Agreement.

 

4.3          Notices.
All notices and other communications required or permitted under this Agreement shall be deemed
to have been duly given and made if in writing and if served by personal delivery to the party for whom intended (which shall include
delivery by Federal Express or similar internationally nationally-recognized service) to the following address, or such other address
as may be designated in writing hereafter by, such party. All communications will be sent to the Company at c/o Stamell & Schager,
LLP, 1 Liberty Plaza 35th Floor, New York, NY 10006 and to Purchaser at the address(es) set forth on each Purchaser's signature
page or at such other address(es) as the Company or Purchaser may designate by ten (10) days advance written notice to the other
parties to this Agreement. 

 

4.4          Waiver.
No delay on the part of any party hereto with respect to the exercise of any right, power, privilege
or remedy under this Agreement shall operate as a waiver thereof, nor shall any exercise or partial exercise of any such right,
power, privilege or remedy preclude any further exercise thereof or the exercise of any other right, power, privilege or remedy.
No modification or waiver by any party hereto of any provision of this Agreement or consent to any departure by any other party
therefrom, shall be effective other than in the specific instance and for the purpose for which given.

 

4.5          Remedies.
The rights, powers, privileges and remedies hereunder are cumulative and not exclusive of any
other right, power, privilege or remedy the parties hereto would otherwise have.

 

    	-5-

    	 

    
 

4.6          Entire
Agreement. This Agreement constitute the entire agreement and understanding among the Purchasers
and the Company, and supersede all prior agreements and understandings, relating to the subject matter hereof.

 

4.7          GOVERNING
LAW; VENUE. This Agreement shall be governed by and construed in accordance
with the laws of THE STATE OF New York, without regard to principles of conflicts of law. venue for any legal action hereunder
shall be the state or federal courts located in the STATE OF New YOrk.

 

4.8          Counterparts.
 This Agreement may be executed in counterparts, each of which shall be deemed an original but
all of which together shall constitute one and the same instrument. Facsimile signatures shall bind the parties hereto to the same
extent as original signatures.

 

4.9          Severability.
Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall,
as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining
provisions of this Agreement and without affecting the validity or enforceability of such provision in any other jurisdiction.

 

4.10          Cross
References. References in this Agreement to any section are, unless otherwise specified, to such
section of this Agreement.

 

4.11          Headings.
The various headings of this Agreement are inserted for convenience only and shall not affect
the meaning or interpretation of this Agreement or any provisions hereof.

 

4.12          Amendment
and Waiver. Except as otherwise provided herein, no modification, amendment or waiver of any
provision of this Agreement will be effective unless such modification, amendment or waiver is approved in writing by the Company
and the Purchaser. The failure of any party to enforce any of the provisions of this Agreement will in no way be construed as a
waiver of such provisions and will not affect the right of such party thereafter to enforce each and every provision of this Agreement.

 

4.13          Binding
Effect. Except as otherwise provided herein, the terms and conditions of this Agreement shall
inure to the benefit of and be binding upon the respective successors and permitted assigns of the parties (including transferees
of the Shares). Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective successors and permitted assigns any rights, remedies, obligations or liabilities under or by reason of this
Agreement, except as expressly provided in this Agreement. 

 

4.14          Construction.
The parties hereto agree that this Agreement is the product of negotiations between sophisticated
parties and individuals, all of whom were represented by separate counsel, and each of whom had an opportunity to participate in,
and did participate in, the drafting of each provision hereof. Accordingly, ambiguities in this Agreement, if any, shall not be
construed strictly or in favor of or against any party hereto but rather shall be given a fair and reasonable construction without
regard to the rule of contra proferentem. As used in this Agreement, the word “including” shall mean “including
without limitation” and the masculine gender shall include the feminine and the neuter gender.

 

[SIGNATURES FOLLOW]

 

    	-6-

    	 

    
 

IN WITNESS WHEREOF, the
parties have executed this Agreement as of December __, 2012.

 

	
        COMPANY:

         

	
        AVRA SURGICAL ROBOTICS, INC.

         

	By:	 
	 	
        Name: Jared B. Stamell

        Title: Vice President

	 	 

 

    	 

    	 

    
 

SECURITIES PURCHASE AGREEMENT

PURCHASER SIGNATURE PAGE

 

          

	
        ____________________________________

        Purchaser Name (Please print or type.)

        ____________________________________

        Signature

        ____________________________________

        Capacity in which signed (if other than individual)

         

         

         

        Dated as of: _________________, 2012

         

        Aggregate number of Shares purchased: _______________

         

        Aggregate Purchase Price: $_______________

         

         

        Purchaser Address:

        (Please print or type.)

         

        ___________________________________________

         

        ___________________________________________

         

        ___________________________________________

         

        ___________________________________________

	 

 

    	 

    	 

    
 

Exhibit A

 

Accredited Investor Questionnaire

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00211-of-00352.parquet"}]]